Article

Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016

Sumanth Gandra1,\*, Sanjeev K Singh2, Dasaratha R Jinka3, Ravishankar Kanithi 4, Ashok K Chikkappa5, Anita Sharma6, Dhanya Dharmapalan7, Anil Kumar Vasudevan2, Onkaraiah Tunga5, Akhila Akula4, Garima Garg6, Yingfen Hsia8, Srinivas Murki9, Gerardo Alvarez-Uria3, Mike Sharland8, Ramanan Laxminarayan1,10

1. Center for Disease Dynamics, Economics & Policy, New Delhi, India
2. Amrita Institute of Medical Sciences, Kochi, Kerala, India
3. Rural Development Trust Hospital, Bathalapalli, Andhra Pradesh, India
4. Sowmya Children’s Hospital, Hyderabad, Telangana, India
5. Rural Development Trust Hospital, Kalyanadurgam, Andhra Pradesh, India
6. Fortis Hospital, Mohali, Punjab, India
7. Yewale Hospital, Mumbai, Maharashtra, India
8. St. Georges University, London, United Kingdom
9. Fernandez Hospital, Hyderabad, Telangana, India
10. Princeton University, New Jersey, USA

\* Correspondence: Email: gandra@cddep.org; Tel.: +91 11 48300364

**Abstract:** The prevalence of antimicrobial resistance in India is among the highest in the world. Antimicrobial use in inpatient settings is an important driver of resistance, but is poorly characterized, particularly in hospitalized children. In this study, conducted as part of the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children (GARPEC) project, we examined the prevalence of and indications of antimicrobial use, as well as antimicrobial agents used among hospitalized children by conducting four point prevalence surveys in six hospitals between February 2016 and February 2017. A total of 681 children were hospitalized in six hospitals across all survey days, and 419 (61.5%) were prescribed one or more antimicrobials (antibacterial, antiviral, antifungal). Antibacterial agents accounted for 90.8% (547/602) of the total antimicrobial prescriptions, of which third-generation cephalosporins (3GCs) accounted for 38.9% (213/547) and penicillin plus enzyme inhibitor combinations accounted for 14.4% (79/547). Lower respiratory tract infection (LRTI) (149 prescriptions; 24.8%) was the most common indication for prescribing antimicrobials. Although national guidelines recommend the use of penicillin and combinations as first-line agents for LRTI, 3GCs were the most commonly prescribed antibacterial agents (55/149 LRTI prescriptions; 36.9%). In conclusion, 61.5% of hospitalized children were on at least one antimicrobial agent with an excessive use of 3GCs and hence an opportunity to limit their inappropriate use.

**Keywords:** point prevalence survey; antimicrobial use; children; hospital; India

Introduction

Antimicrobial resistance is rising across the globe, with India reporting among the highest prevalence [[1](#_ENREF_1),[2](#_ENREF_2)]. A recent study reported that resistance to last-resort antimicrobials increased between 2008 and 2014 [[3](#_ENREF_3)]. In 2014, 57% of *Klebsiella pneumoniae* and 10% of *Escherichia coli* blood culture isolates were observed to be carbapenem resistant. The high proportion of bacterial infections due to extended spectrum beta-lactamase (ESBL) producing organisms is one reason for the high consumption of carbapenems in India. Among 51 countries for which antimicrobial resistance surveillance data were available in 2014, India had the highest proportion of third-generation cephalosporin resistant *E. coli* (83%), an indirect marker for ESBL production [[4](#_ENREF_4)].

Antimicrobial selection pressure is a primary driver of resistance development [[5](#_ENREF_5)], and there is an urgent need to reduce antimicrobial overuse and misuse. Surveillance of antimicrobial use in hospitals can provide insight into patterns of antimicrobial use, help highlight differences in prescribing practices among hospitals, and identify opportunities for improvement. Information on antimicrobial use from point prevalence surveys (PPSs) could be used to design, implement, and assess the effects of antimicrobial policies [[6](#_ENREF_6)]. To date, only one multicenter (>2 hospitals) study describing antimicrobial use among hospitalized children has been published in India [[7](#_ENREF_7)]. However, this study did not collect information on the total number of children admitted to various wards and thus could not estimate the rate of antimicrobial use per patient. In this study, we examined the prevalence of and indications of antimicrobial use, as well as the antimicrobial agents used among hospitalized children by conducting four PPSs in six hospitals in India.

Results

At the six participating hospitals, the total number of beds for all four survey days ranged from 24 to 517, and the bed occupancy ranged from 15.1% to 79.8% (Table 1).

**Table 1.** Characteristics, bed occupancy, and antimicrobial prescription of the six hospitals in India in 2016

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Hospital ID** | **Hospital Characteristics** | **Total Beds** | **Total Patients (N)** | **Bed Occupancy (%)** | **Intensive Care Beds (Yes/No)** | **Patients on Antimicrobials (N)** | **Patients on Antimicrobials (%)** |
| A\* | Rural general hospital | 149 | 92 | 61.7 | Y | 51 | 55.4 |
| B | Stand-alone pediatric  | 112 | 79 | 70.5 |   Y | 57 | 72.2 |
| C\* | Rural general hospital | 119 | 95 | 79.8 | N | 76 | 80.0 |
| D# | Tertiary care hospital | 517 | 385 | 74.5 | Y | 212 | 55.1 |
| E\* | Tertiary care hospital | 24 | 14 | 58.3 | Y | 13 | 92.9 |
| F\*\* | Stand-alone pediatric  | 106 | 16 | 15.1 | Y | 10 | 62.5 |
| All |  | 1027 | 681 | 66.3 |  | 419 | 61.5 |

*Note*: Hospitals A, B, and F have only medical intensive care units; Hospitals D and E have surgical intensive care beds available in addition to medical.

\*Did not participate in the first point prevalence survey.

\*\*Did not participate in the second point prevalence survey.

# Has teaching services in pediatric departments.

A total of 681 children were hospitalized in six hospitals across all survey days, and 419 (61.5%) were prescribed one or more antimicrobials. The percentage of children on antimicrobials in the six hospitals ranged from 55.1% to 92.9% (Table 1). One antimicrobial was prescribed to 291 patients, two antimicrobials were prescribed to 85 patients, and three or more were prescribed to 43 patients. The percentages of patients on antimicrobials for the four PPSs were 61.3% (73/119), 59.4% (104/175), 63.6 % (133/209), and 61.2% (109/178), respectively.

Of the 419 children receiving antimicrobials, 147 (35.1%) were less than one year old, and 248 (59.2%) were male (Table 2).

**Table 2.** Percentages of hospitalized children on antimicrobials in six hospitals in India in 2016

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Number of Children****(*N* = 419)** | **Percentage of Children** | **Number of Prescriptions****(*N* = 602)** | **Percentage of Prescriptions** |
| Underlying comorbid conditions | 256 | 61.1 | 359 | 59.6 |
| No underlying disease | 163 | 38.9 | 243 | 40.4 |
| **Age category** |  |  |  |  |
| Age <1 | 147 | 35.1 | 197 | 32.7 |
| Age 1–6 | 173 | 41.2 | 255 | 43.2 |
| Age 7–12 | 79 | 18.8 | 118 | 19.6 |
| Age >12 | 20 | 4.8 | 32 | 5.5 |
| **Gender** |  |  |  |  |
| Male | 248 | 59.2 | 354 | 58.6 |
| **Ward activity** |  |  |  |  |
| Intensive care units | 90 | 21.5 | 138 | 22.9 |
| General wards | 329 | 78.5 | 464 | 77.1 |
| **Diagnosis\*** |  |  |  |  |
| Lower respiratory tract infection (LRTI) | 117 | 27.9 | 149 | 24.8 |
| Sepsis | 67 | 15.9 | 90 | 15.0 |
| Prophylaxis for surgical disease | 50 | 11.9 | 77 | 12.8 |
| Treatment for surgical disease | 34 | 8.1 | 64 | 10.6 |
| Prophylaxis for medical problems | 29 | 6.9 | 41 | 6.6 |
| Other | 80 | 19.0 | 116 | 19.3 |
| Upper respiratory infections (URTI) | 17 | 4.1 | 23 | 3.8 |
| Urinary tract infections (UTI) | 18 | 4.3 | 22 | 3.7 |
| GI tract infections | 19 | 4.5 | 21 | 3.5 |
| **Indication\*** |  |  |  |  |
| Community acquired infection (CAI) | 233 | 55.6 | 313 | 52.0 |
| Healthcare associated infection (HAI) | 40 | 9.5 | 55 | 9.1 |
| Unknown | 79 | 18.9 | 116 | 19.3 |
| Prophylaxis (medical and surgical) | 79 | 18.9 | 118 | 19.6 |

\* Total can be more than 100% as one patient can have more than one diagnosis

Only one hospital (Hospital D) had two dedicated surgical wards. The remaining five hospitals had general pediatric wards, where both medical and surgical patients were admitted. Pediatric intensive care units were present in five hospitals, of which two had dedicated surgical intensive care units. General pediatric wards accounted for 78.5% (329) of children on antimicrobials, and intensive care units accounted for the remaining 21.5% (90) (Table 2). The percentage of patients on antimicrobials was significantly higher in intensive care units than in general pediatric wards (73.4% vs. 59.0%; *P* = 0.003). The average number of antimicrobials per patient was higher in intensive care units (mean 1.5; range 1–4) than in general pediatric wards (mean 1.4; range 1–5). In 419 patients with an antimicrobial prescription, 343 (81.8%) were prescribed for treatment of active infection and 76 (18.2%) for prophylaxis. Lower respiratory tract infection (LRTI) (117, 27.9%), sepsis (66, 15.7), and prophylaxis for surgical disease (49, 11.7%) were the three most common reasons for prescribing antimicrobials (Table 2).

Of the 602 total antimicrobial prescriptions, 313 (52%) were for community-acquired infections (CAIs), 55 (9.1%) were for healthcare associated infections (HAI), and 116 (19.3%) were for unknown indications (CAI or HAI) (Table 2). Of the 602 prescriptions, 118 (19.6%) were for medical and surgical prophylaxis. Among the 313 prescriptions for CAIs, 283 (90.4%) were empiric, whereas 35 (63.6%) of 55 prescriptions for HAIs were empiric. Of the 313 antimicrobial prescriptions for CAIs, the majority were prescribed for LRTI (133 prescriptions; 42.5%) and sepsis (54 prescriptions; 17.3%).

Antibacterial agents accounted for 90.8% (547 of 602) of total antimicrobial prescriptions. Of the 547 antibacterial prescriptions, the three most common classes of antibiotics prescribed were third-generation cephalosporins (213 of 547 prescriptions; 38.9%), penicillin plus enzyme inhibitor combinations (78 of 547 prescriptions; 14.3%), and aminoglycosides (57 of 547 prescriptions; 10.4%) (Table 3).

**Table 3.** Antimicrobial prescriptions for all indications among hospitalized children in six hospitals in India in 2016

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|   | **All** | **Hospital A** | **Hospital B** | **Hospital C** | **Hospital D** | **Hospital E** | **Hospital F** |
| Children on ≥1 antimicrobials | 432 | 93 | 108 | 95 | 388 | 14 | 14 |
|  |   |   |   |   |   |   |   |
| Total number of prescriptions | **602** | **77** | **90** | **91** | **306** | **26** | **12** |
| 3rd-gen. cephalosporins | **213** | 25 | 44 | 16 | 108 | 12 | 8 |
| Penicillin + enzyme inhibitors | **78** | 13 | 3 | 44 | 16 | 1 | 1 |
| Others\* | **73** | 13 | 16 | 19 | 22 | 3 | 0 |
| Aminoglycosides | **57** | 11 | 4 | 1 | 31 | 10 | 0 |
| Penicillins  | **35** | 4 | 1 | 0 | 29 | 0 | 1 |
| Metronidazole | **33** | 0 | 2 | 2 | 29 | 0 | 0 |
| Carbapenems | **27** | 2 | 3 | 1 | 21 | 0 | 0 |
| Fluoroquinolones | **20** | 1 | 6 | 0 | 13 | 0 | 0 |
| 1st/2nd-gen. cephalosporins | **18** | 0 | 0 | 0 | 18 | 0 | 0 |
| Macrolides | **16** | 1 | 6 | 2 | 6 | 0 | 1 |
| Glycopeptides | **14** | 3 | 3 | 0 | 8 | 0 | 0 |
| Trimethoprim/sulfa | **12** | 3 | 1 | 4 | 4 | 0 | 0 |
| Tetracycline | **6** | 1 | 1 | 2 | 1 | 0 | 1 |

**\****Others* included chloramphenicol, clindamycin, linezolid, doxycycline, tigecycline, colistin, antituberculosis, antifungals, antivirals, and antimalarial.

The top three classes of antibacterial agents and their order were similar in each of the four PPSs. Carbapenems and fluoroquinolones accounted for less than 5% each of total antibacterial prescriptions, respectively (Table 3).

Of the prescriptions for carbapenems, 55.5% (15/27) were prescribed in intensive care units. The top three reasons for prescribing carbapenems were sepsis (4 HAI and 1 CAI), LRTI (3 CAI and 1 HAI), and central nervous system infections (2 CAI and 1 unknown). Overall, the three most commonly prescribed antimicrobials were ceftriaxone (111 of 602 prescriptions; 18.4%), amoxicillin-clavulanic acid (69 of 602 prescriptions; 11.5%), and cefotaxime (58 of 602 prescriptions; 9.6%) (Figure 1).



**Figure 1.** Prescribed antimicrobials among hospitalized children, ranked by overall drug
utilization 75% (DU75%)

The five diagnoses associated with the highest rates of antimicrobial prescribing were LRTI (149 of 602 prescriptions; 24.8%), sepsis (90 of 602 prescriptions; 15%), prophylaxis for surgical disease (77 of 602 prescriptions; 12.8%), treatment of surgical disease (64 of 602 prescriptions; 10.6%), and prophylaxis for medical problems (41 of 602 prescriptions; 6.8%) (Table 2). The two most commonly prescribed antibacterial classes for LRTI were third-generation cephalosporins (55 of 149 prescriptions; 36.9%) and penicillin plus enzyme inhibitor combinations (46 of 149 prescriptions; 30.9%). For LRTI, third-generation cephalosporins were mainly used as monotherapy (38/55) and in combination in 17 other cases, mostly with macrolides (5/17). The two most common antibacterial agents prescribed for sepsis were the third-generation cephalosporins (40 of 90 prescriptions; 44.4%) and amikacin (11 of 90 prescriptions; 12.2%). For sepsis cases, third-generation cephalosporins were mainly used as monotherapy (26/40) and in combination in 14 other cases, mostly with amikacin (8/14).

In cases of prophylaxis for surgical disease, the two most commonly prescribed antibacterial classes were third-generation cephalosporins (29 of 64 prescriptions; 37.7%) and aminoglycosides (16 of 64 prescriptions; 25%). Third-generation cephalosporins were used as monotherapy in 9 cases and in combination in 20 other cases, mostly with aminoglycosides (8/20) and with both aminoglycosides and metronidazole (4/20). Third-generation cephalosporins were the most commonly used antibacterial agents (14/41) used for medical prophylaxis. They were used as monotherapy in six patients in combination mainly with aminoglycosides in eight patients (4/8).

Discussion

To the best of our knowledge, this is the first published multicenter study to estimate the prevalence of antimicrobial use among hospitalized children in India. The percentage of hospitalized children who received at least one antimicrobial agent was 61.5% in this study. In the global Antibiotic Resistance and Prescribing in European Children (ARPEC) PPS study conducted in 2012, involving 226 hospitals from 41 countries, the overall percentage of hospitalized children on antimicrobials was 42.5%, which was much lower than the 61.5% in our study [[8](#_ENREF_8)]. The percentage of patients on antimicrobials in our study was higher than reported in Turkey (54.6%) [[9](#_ENREF_9)], Italy (47%) [[10](#_ENREF_10)], Australia (46%) [[11](#_ENREF_11)], the United Kingdom (40.9%) [[12](#_ENREF_12)], Latvia (39%) [[13](#_ENREF_13)], and the United States (33%) [[14](#_ENREF_14)]. However, it was lower than in Iran (66.6%) [[15](#_ENREF_15)] and China (78.2%) [[16](#_ENREF_16)]. Consistent with previous studies, we observed that the majority of the antimicrobial usage was for therapeutic purposes rather than prophylaxis [[8](#_ENREF_8),[10–12](#_ENREF_10),[15](#_ENREF_15)].

LRTI was the most common indication for prescribing antimicrobials, a finding consistent with PPSs among hospitalized children in several other countries [[10–13](#_ENREF_10)]. Third-generation cephalosporins were the most commonly prescribed antibiotics for LRTI in this study. Similar findings were reported by another Indian study, which reviewed antibiotic prescription practices among hospitalized children in two private hospitals in Central India [[17](#_ENREF_17)]. However, the Indian National Center for Disease Control and Prevention (NCDC) guidelines [[18](#_ENREF_18)] and INDIACLEN task force guidelines for pneumonia [[19](#_ENREF_19)] recommend ampicillin or ampicillin plus gentamicin or amoxicillin-clavulanic acid as first-line therapy for LRTI among hospitalized children older than two months. Third-generation cephalosporins are recommended in hospitalized children only when they deteriorate on first-line agents.

Consistent with our findings, third-generation cephalosporins were the most commonly prescribed antimicrobials in Eastern Europe (35.7%) and Asia (28.6%) in the global ARPEC study [[8](#_ENREF_8)], as well as in Turkey (18.4%) [[9](#_ENREF_9)], Italy (20%) [[10](#_ENREF_10)], Latvia (28%) [[13](#_ENREF_13)], and Iran (43.5%) [[15](#_ENREF_15)]. However, in Australia and the United Kingdom, penicillin plus enzyme inhibitor combinations were the most commonly prescribed antimicrobials [[11](#_ENREF_11),[12](#_ENREF_12)]. Carbapenem prescription in this study was lower than in Turkey (12.7%) [[9](#_ENREF_9)], Italy (6%) [[10](#_ENREF_10)], and Iran (5.2%) [[15](#_ENREF_15)], but higher than in Australia (3.2%) [[11](#_ENREF_11)] and Latvia (0.5%) [[13](#_ENREF_13)]. However, it is possible that carbapenem consumption has been underestimated because of the lack of representation of tertiary care centers with large numbers of intensive care unit beds in this study.

The study has several strengths. First, the repeated PPSs in the six hospitals increased the robustness of our estimates of antimicrobial prescription among hospitalized children. Second, the six participating hospitals represented diverse settings that are commonly seen in India. Two hospitals were small stand-alone children hospitals in urban areas, two were part of a rural general hospital, and two were part of large tertiary care referral centers. Thus we were able to capture antimicrobial prescribing practices in different hospital settings. Third, we examined for the variation of antimicrobial use at different times of the year. Interestingly, the percentages of children on antimicrobials and the antimicrobial prescription patterns in each of the four PPSs were similar when compared with combined data from all four PPSs. We did not observe any temporal variation in antimicrobial prescribing.

The study also has several limitations, however. First, we did not collect data on duration of therapy, nor the microbiology and antimicrobial susceptibility results, which could help indicate the appropriateness of antimicrobial prescribing. Second, although we included hospitals with different characteristics, we did not include large academic centers and hospitals from all regions of India. This would require a much larger study. Thus, our results may not be generalizable to all healthcare settings and geographic regions of the country. Similarly, as all hospitals included in the study were from private sector, the results may not be generalizable to public sector hospitals. The choice of antibiotics may differ in public hospitals as the national and state drug policies often define the types of antibiotics procured and prescribed in the public sector hospitals. The public sector hospitals are also obliged to follow national prescribing guidelines. Third, five out of six hospitals did not have dedicated surgical wards or other specialized units such as hematology-oncology or cardiology, which limited our ability to study variation of antimicrobial use across different hospital units. Fourth, with Hospital D having most number of beds and patients in the study, the results could have been biased affecting the representativeness of the data. Fifth, the date of the survey was chosen as per the convenience of the site principal investigator within the specified months. However, we have not taken additional steps to minimize the Hawthorne effect. As the physicians knew that their antimicrobial prescriptions were being studied, the results might have been affected. Sixth, 79 (19%) of the prescriptions had unknown indication (not known whether it was community acquired or healthcare associated), however, we have not taken additional efforts to identify the indications.

Our study identified an opportunity to improve antimicrobial use for LRTI among hospitalized children. The current guidelines recommend the use of third-generation cephalosporins only when there is deterioration in effectiveness of first-line agents. However, in our study, the majority of hospitalized children with LRTI were on third-generation cephalosporins. A recent study assessing the antibiotic susceptibility of the major bacterial pathogens isolated from community-acquired pneumonia among both adults and children in India indicated high susceptibility to first-line agents (ampicillin and amoxicillin-clavulanic acid) [[20](#_ENREF_20)]. In this study, 91.8% of *Streptococcus pneumoniae* isolates were susceptible to amoxicillin. Similarly, 91.1% of *Haemophilus influenzae* isolates were susceptible to ampicillin, and 97% of the *H. influenzae* isolates were susceptible to amoxicillin-clavulanic acid [[20](#_ENREF_20)]. This study reinforces that third-generation cephalosporins can be avoided as first-line therapy for LRTI. We also observed that third-generation cephalosporins were the most commonly used antibiotics for surgical prophylaxis. However, the published international guidelines recommend use of first- and second-generation cephalosporins for surgical prophylaxis instead of third-generation cephalosporins [[21](#_ENREF_21)].

Reviewing national antimicrobial resistance surveillance data obtained both from adults and children, in 2014, 83% of the *E. coli* isolates were resistant to third-generation cephalosporins in India, which was much higher than in Australia (9%), the United Kingdom (11%), Argentina (14%), the United States (16%), South Africa (19%), and China (62%) [[22](#_ENREF_22),[23](#_ENREF_23)]. Use of third-generation cephalosporins is associated with increased the risk of colonization with ESBL-producing bacteria [[24](#_ENREF_24)]. Third-generation cephalosporin exposure in children could lead to colonization at a very young age, which could facilitate the spread of ESBL-producing bacteria to other family members, leading to a further increase in ESBL Enterobacteriaceae infections and subsequently the consumption of carbapenems in India. Our findings indicate the need for increased compliance with NCDC and INDIACLEN treatment guidelines for the management of LRTI in children.

In conclusion, 61.5% of the hospitalized children were on at least one antimicrobial agent. We observed an excessive use of third-generation cephalosporins for LRTI. There is an opportunity to limit the use of third-generation cephalosporins by following the recommended national treatment guidelines for management of LRTI.

Methods

As part of the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children (GARPEC) study, the participating hospitals were asked to conduct a one-day cross-sectional hospital based PPSs in all pediatric and neonatal wards four times between February 1, 2016, and February 28, 2017. The Antibiotic Resistance and Prescribing in European Children (ARPEC) project PPS methodology was utilized for this study [[8](#_ENREF_8)]. Four single-day PPSs on antimicrobial use were conducted between February 1, 2016, and February 28, 2017. The first PPS was conducted between February 1 and March 31, 2016; the second between May 1 and June 30, 2016; the third between September 1 and October 31, 2016; and the fourth between December 1, 2016, and February 28, 2017. Four PPSs were conducted to increase the precision of measurement of antimicrobial use and to examine the variation of antimicrobial use at different time points.

Each hospital needed to register providing the name, geographic location and type of hospital (primary, secondary and tertiary level and teaching vs. nonteaching hospital). Hospitals were asked to conduct the survey only on a weekday during the designated months of each round of PPS. All neonates and pediatric hospitalized patients younger than 18 years of age, present in the ward at 8 am, were included in the survey. Detailed data were recorded only for patients with an active antimicrobial prescription at 8 am on the day of survey.

At the time of initiation of the study on February 1st, 2016, five hospitals were enrolled into the study. Three additional hospitals were enrolled by May 1st, 2016 and did not participate in the first round of PPS. Among the eight hospitals, two were rural general trust hospitals, three were stand-alone private children’s hospitals, two were private tertiary care hospitals and one was a private mother and child care center with inborn neonatal services. One tertiary care hospital had teaching services in pediatrics and neonatal departments. Two stand-alone pediatric hospitals and the mother and child care center had teaching services in neonatal departments. PPSs were conducted in the neonatal intensive care units and neonatal wards of all eight hospitals and the pediatric units (including pediatric intensive care units) of only six hospitals (one hospital had only neonatal services and the other hospital restricted the study to neonatal units). In this study, we examined the antimicrobial use patterns among the pediatric units of six hospitals. Antimicrobial use in neonatal intensive care units and general neonatal wards were not examined in this study.

Hospital, department, and deidentified patient data were collected using a standardized web-based electronic data entry form on the Research Electronic Data Capture (REDCap)® developed for the GARPEC project. For children receiving antimicrobials (antibiotics, antifungal and antivirals, antiparasital agents), data were collected on patient sex, age, weight, ventilation status, comorbid conditions, number of antimicrobials, antimicrobial name, dose per administration, dose units, number of doses each day, route of administration, reason for treatment, treatment indication (community versus healthcare associated) or prophylaxis, and whether treatment was empirical or targeted. We included all diagnoses for which antimicrobials were prescribed even if there was more than one diagnosis. Ethics approval was received for all participating hospitals from their respective institutional human research ethics committees.

Categorical variables were expressed as percentages, and the chi-square test or Fisher’s exact test was used, as appropriate, for comparisons. Statistical significance was defined as *P*  <  0.05. The statistical analyses were performed using STATA 12.1 (StataCorp, College Station, Texas, USA).

**Acknowledgments:** SG and RL are supported by Global Antibiotic Resistance Partnership (GARP), funded by Bill & Melinda Gates Foundation.

**Author Contributions:** MS, SG, and RL conceptualized and designed the study. SG and YH performed the analysis and created figures and tables. SG drafted the manuscript. All authors interpreted the analysis. All authors reviewed, revised, and approved the final manuscript.

**Conflicts of Interest:** All authors report no conflicts of interest.

References

1. Laxminarayan, R.; Matsoso, P.; Pant, S.; Brower, C.; Rottingen, J.A.; Klugman, K.; Davies, S. Access to effective antimicrobials: A worldwide challenge. *Lancet* **2016**, *387*, 168–175.

2. Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.; Wertheim, H.F.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H., et al. Antibiotic resistance: The need for global solutions. *Lancet Infect. Dis.* **2013**, *13*, 1057–1098.

3. Gandra, S.; Mojica, N.; Klein, E.Y.; Ashok, A.; Nerurkar, V.; Kumari, M.; Ramesh, U.; Dey, S.; Vadwai, V.; Das, B.R., et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. *Int. J. Infect. Dis.* **2016**.

4. Gelband H, M.-P.M.; Pant S.; Gandra S.; Levinson J.; Barter D.; White A.; Laxminarayan R. *The State of the World’s Antibiotics, 2015*. Center for Disease Dynamics, Economics & Policy: 2015.

5. World Health Organisation (WHO). WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health. Available online: <http://www.who.int/mediacentre/news/releases/2014/amr-report/en/> (accessed on March 18, 2017).

6. Skoog, G.; Struwe, J.; Cars, O.; Hanberger, H.; Odenholt, I.; Prag, M.; Skarlund, K.; Ulleryd, P.; Erntell, M. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: Data for actions 2003–2010. *Euro Surveill.* **2016**, *21*.

7. Sanjeev Singh, T.J.; Versporten, A.; Sengupta, S.; Fini, P.; Sharland, M.; Kumar, K.R.; Goossens, H. A point prevalence surveillance study from pediatric and neonatal specialty hospitals in India. *J. Pediatric Infect. Dis.* **2014**, *9*, 151–155.

8. Versporten, A.; Bielicki, J.; Drapier, N.; Sharland, M.; Goossens, H. The worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children. *J. Antimicrob. Chemother.* **2016**, *71*, 1106–1117.

9. Ceyhan, M.; Yildirim, I.; Ecevit, C.; Aydogan, A.; Ornek, A.; Salman, N.; Somer, A.; Hatipoglu, N.; Camcioglu, Y.; Alhan, E., et al. Inappropriate antimicrobial use in Turkish pediatric hospitals: A multicenter point prevalence survey. *Int. J. Infect. Dis.* **2010**, *14*, e55–61.

10. De Luca, M.; Dona, D.; Montagnani, C.; Lo Vecchio, A.; Romanengo, M.; Tagliabue, C.; Centenari, C.; D’Argenio, P.; Lundin, R.; Giaquinto, C., et al. Antibiotic prescriptions and prophylaxis in Italian children: Is it time to change? Data from the ARPEC project. *PloS One* **2016**, *11*, e0154662.

11. Osowicki, J.; Gwee, A.; Noronha, J.; Palasanthiran, P.; McMullan, B.; Britton, P.N.; Isaacs, D.; Lai, T.; Nourse, C.; Avent, M., et al. Australia-wide point prevalence survey of the use and appropriateness of antimicrobial prescribing for children in hospital. *Med. J. Aust.* **2014**, *201*, 657–662.

12. Gharbi, M.; Doerholt, K.; Vergnano, S.; Bielicki, J.A.; Paulus, S.; Menson, E.; Riordan, A.; Lyall, H.; Patel, S.V.; Bernatoniene, J., et al. Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK. *BMJ Open* **2016**, *6*, e012675.

13. Sviestina, I.; Mozgis, D. Antimicrobial usage among hospitalized children in Latvia: A neonatal and pediatric antimicrobial point prevalence survey. *Medicina (Kaunas, Lithuania)* **2014**, *50*, 175–181.

14. Pakyz, A.L.; Gurgle, H.E.; Ibrahim, O.M.; Oinonen, M.J.; Polk, R.E. Trends in antibacterial use in hospitalized pediatric patients in United States academic health centers. *Infect. Control Hosp. Epidemiol.* **2009**, *30*, 600–603.

15. Fahimzad, A.; Eydian, Z.; Karimi, A.; Shiva, F.; Sayyahfar, S.; Kahbazi, M.; Rahbarimanesh, A.; Sedighi, I.; Arjmand, R.; Soleimani, G., et al. Surveillance of antibiotic consumption point prevalence survey 2014: Antimicrobial prescribing in pediatrics wards of 16 Iranian hospitals. *Arch. Iran. Med.* **2016**, *19*, 204–209.

16. Xie, D.S.; Xiang, L.L.; Li, R.; Hu, Q.; Luo, Q.Q.; Xiong, W. A multicenter point-prevalence survey of antibiotic use in 13 Chinese hospitals. *J. Infect. Public Health* **2015**, *8*, 55–61.

17. Sharma, M.; Damlin, A.; Pathak, A.; Stalsby Lundborg, C. Antibiotic prescribing among pediatric inpatients with potential infections in two private sector hospitals in Central India. *PloS One* **2015**, *10*, e0142317.

18. National Center for Disease Control. National Treatment Guidelines for Antimicrobial use in Infectious Diseases. 2016. Available online: <http://pbhealth.gov.in/amr_guideline7001495889.Pdf> (accessed on January 26, 2017).

19. Rational use of antibiotics for pneumonia. *Indian Pediatr.* **2010**, *47*, 11–18.

20. Torumkuney, D.; Chaiwarith, R.; Reechaipichitkul, W.; Malatham, K.; Chareonphaibul, V.; Rodrigues, C.; Chitkins, D.S.; Dias, M.; Anandan, S.; Kanakapura, S., et al. Results from the survey of antibiotic resistance (SOAR) 2012–14 in Thailand, India, South Korea and Singapore. *J. Antimicrob. Chemother.* **2016**, *71*, 3628.

21. Bratzler, D.W.; Dellinger, E.P.; Olsen, K.M.; Perl, T.M.; Auwaerter, P.G.; Bolon, M.K.; Fish, D.N.; Napolitano, L.M.; Sawyer, R.G.; Slain, D., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg. Infect.* **2013**, *14*, 73–156.

22. Resistancemap. Center for Disease Dynamics, Economics & Policy. Available online: <https://resistancemap.cddep.org/resmap/resistance/> (accessed on September 24, 2015).

23. Hu, F.P.; Guo, Y.; Zhu, D.M.; Wang, F.; Jiang, X.F.; Xu, Y.C.; Zhang, X.J.; Zhang, C.X.; Ji, P.; Xie, Y., et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. *Clin. Microbiol. Infect.* **2016**, *22 Suppl 1*, S9–14.

24. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. *Clin. Microbiol. Rev.* **2005**, *18*, 657–686.

© 2017 by the authors. Submitted for possible open access publication under the
terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).